Framework for the Ongoing Supply of Plasmid
A Contract Award Notice
by CENTRE FOR PROCESS INNOVATION
- Source
- OJEU
- Type
- Framework (Supply)
- Duration
- 2 year (est.)
- Value
- ___
- Sector
- HEALTH
- Published
- 27 Jul 2022
- Delivery
- To 26 Jul 2024 (est.)
- Deadline
- n/a
Concepts
Location
Redcar
2 buyers
1 supplier
- Unnamed None
Description
In response to the COVID-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. This tender is split into three lots: 1. To generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli. 2. From the MCB, supply 10g of purified linearised plasmid manufactured according to GMP.(To simplify the tendering process, CPI will free issue the restriction enzyme for linearization to the successful bidder) 3. Provision of the combined services of Lot 1 and 2.
Lot Division
| 1 | Generation and validation of a Master Cell Bank for plasmid production In response to the COVID-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. CPI requires a supplier to generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli. Award Criteria
| ||||||||
| 2 | Supply 10g of purified linearised plasmid In response to the COVID-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. CPI requires a supplier to supply 10g of purified linearised plasmid manufactured according to GMP Award Criteria
| ||||||||
| 3 | Supply 10g of purified linearised plasmid In response to the COVID-19 Vaccine manufacture programme, CPI need to secure supply of linearised plasmid to help develop a self-amplifying RNA Vaccine. CPI requires a supplier to generate and validate a MCB for plasmid production, starting with a provided plasmid template in an appropriate strain of E. coli. From the MCB, they are expecited supply 10g of purified linearised plasmid manufactured according to GMP.(To simplify the tendering process, CPI will free issue the restriction enzyme for linearization to the successful bidder) Award Criteria
|
Award Detail
| 1 | Unnamed (None)
|
| 2 | Unnamed (None)
|
| 3 | Unnamed (None)
|
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Award on basis of price and quality.
Legal Justification
The COVID-19 outbreak has given rise to an urgent need for the Plasmid for CPI as it is required in response for the urgent need to develop a vaccine. This does not give CPI sufficient time to comply with the standard open procedure timescales for this procurement. CPI considers this to be a state of urgency which it has duly substantiated. Accordingly, CPI is using the accelerated time limits permitted under the Public Contract Regulations 2015 (regulation [27(5) for the open procedure) in respect of this procurement.
Reference
- OJEU 410871-2022